Navigation Links
Cellectar Expands Clinical Management Team
Date:10/3/2007

mpany expects to initiate Phase I clinical trails in mid-2008.

About Cellectar

Cellectar LLC is a radiopharmaceuticals company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar's novel product candidates combine lipid-like molecules, phospholipid ethers (PLEs), with radioisotopes that destroy malignant cells. Cellectar's products' unique mechanism of action is based on their selective accumulation and retention in malignant tumors and not normal cells. The company's operations are based in Madison, WI. Cellectar has previously raised approximately $9.0 million from angel investors; including Continuum Investment Partners. For further information about Cellectar, visit the company website at http://www.cellectar.com.

About CLR1404

Cellectar's lead product candidate, CLR1404, is a phospholipid ether (PLE) combined with the radiolabel 131Iodine. Preclinical studies have shown that this compound is selectively retained in malignant cells. In pre-clinical studies, CLR1404 was taken up and retained in 100% of the 40+ malignant tumor types tested. Cellectar plans to move the compound into phase I clinical trials in mid-2008.


'/>"/>
SOURCE Cellectar LLC
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Genetic Analysis Systems Enter the Clinical Mainstream
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)...n January 2009 and Final Trial ...t. 13 /- Neurobiological,Te...nnounced that following a,meeting with the U.S. Fo...(TM) (ancrod) Phase 3 clinical program for acute i...nd analyze data from its two concurrently,running ...
(Date:10/13/2008)... Facet Solutions, Inc. today,announced the complet...S,IDE Pilot Study. The results show a 78% reductio...n 80% reduction in Visual Analog Scores (VAS) for,... for Facet Solutions,added, "We are very pleased ...demonstrate significant pain relief but the safety...
(Date:10/12/2008)...signed for more uniform drug ..., Oct. 12 /- Boston,Scienti...rehensive data from,the TAXUS ATLAS clinical progr... single-arm, historically controlled trials, which...ng Stent System in a variety of,lesions and patien...
(Date:10/10/2008)...0 /-,XTENT, Inc. (Nasdaq: ...ng-term follow-up data from the CUSTOM I, II and I... Research Foundation,s (CRF) twentieth annual,Tran...g in Washington, DC.,The CUSTOM clinical trials ar...safety and efficacy of the Custom NX(R) drug eluti...
Breaking Medicine Technology:Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data 2Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data 3Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data 4Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 2Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 3Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 4Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 5Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 6XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week 2Eklin Medical Reports Record Revenues for 2007 3303 1Eklin Medical Reports Record Revenues for 2007 3303 2Eklin Medical Reports Record Revenues for 2007 3303 3Hayes Clinical Labs to Market MedeFiles Proprietary Electronic Medical Record Management Solution to Patients 3301 1Hayes Clinical Labs to Market MedeFiles Proprietary Electronic Medical Record Management Solution to Patients 3301 2Hayes Clinical Labs to Market MedeFiles Proprietary Electronic Medical Record Management Solution to Patients 3301 3Hayes Clinical Labs to Market MedeFiles Proprietary Electronic Medical Record Management Solution to Patients 3301 4Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th 11903 1Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th 11903 2Centene Foundation for Quality Healthcare Awards Grant to Texas Parent to Parent 11901 1Centene Foundation for Quality Healthcare Awards Grant to Texas Parent to Parent 11901 2Centene Foundation for Quality Healthcare Awards Grant to Texas Parent to Parent 11901 3
...Analysis Shows Statistically Significant Changes i...alif., March 26, 2007 /PRNewswire-FirstCall/ --,Al...e initial,results from its Phase IIa clinical tria...c patients with acute agitation. The 10 mg,dose of...rial,which was a statistically-significant reduct...
...d CAPTURE 2 Findings Suggest Improved Outcomes in ...26, 2007 /PRNewswire-FirstCall/ --,Positive 30-day...tid stenting can be performed with positive result...ience in real-world,(non-clinical trial) settings ...urgery. Interim results from the first 1,500,patie...
Other Medicine Technology:Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 2Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 3Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 4Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 5Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 6Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 2Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 3Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 4
(Date:10/13/2008)...tion of low plasma levels of antioxidants and blue...rtain forms of the eye disease age-related macular...October issue of Archives of Ophthalmology , one ...s vulnerable to the damaging effects of light," th...rticle. "While wavelengths in the UV radiation ran...
(Date:10/13/2008).../ -- As the first-ever report,by the United Nation...heduled to be presented to Member States today, th...rease in the number of countries it serves.,Accord...o prevent and treat,fistula in over 45 countries i...unched in 2003, it covered 12 countries., The Sec...
(Date:10/13/2008)...rages Latinos to Get Tested, LOS ANGELES, Oct. 13...t half of all newly diagnosed HIV/AIDS cases,repor...ationally., -- A week of activities aimed at rais...esting to coincide with National Latino AIDS Aware...Our Community, Our Responsibility: Latinos in Acti...
(Date:10/13/2008)...en, study found , , MONDAY, Oct. 13 (Hea...re your brain shrinks, a new study has found. ,...ot, you,re going to hurt your brain," said Rajesh ...d experimental therapeutics at the Texas A&M H... something we knew, but this is a huge study that ...
Breaking Medicine News(10 mins):Health News:Sunlight exposure plus low antioxidant levels may place older adults at risk for eye disease 2Health News:Campaign to End Fistula Quadruples In Size, Reaching Over 45 Countries, Says New Report 2Health News:Campaign to End Fistula Quadruples In Size, Reaching Over 45 Countries, Says New Report 3Health News:Nearly Half of Newly Diagnosed HIV/AIDS Cases in Los Angeles County Are Among Latinos 2Health News:Excess Drinking Shrinks the Brain 2
...Reports say that the health providers do not treat...spect and they are not provided with correct diagn...cted in more than 1,000 men with prostate cancer a...an 22% felt they were given their diagnosis insens...
...A cloud of controversy has surrounded The Thiruvan...aiming that a one-year-old girl who had received a... tested positive for HIV infection. // According ...o is HIV-positive, was given blood, which had been...
...Shortness of breath can be a more reliable indicat... finding that such patients have a higher risk of ...diac pain or other symptoms. //The general notion ... cardiac disease has been disapproved by the findi...
...Researchers from University of Cape Town, South Af... and treat cervical cancer prevention programs in ...ow resource settings exclusively for developing an...showed that the test and treat program was very mu...
Other Medicine News:Health News:Prostate cancer patients not happy with health providers 2Health News:Shortness Of Breath A More Reliable Indicator Of High Risk Cardiac Disease 2Health News:Two screen test and treat screening for cervical cancer 2
BD Persist Plus protective barrier skin preps with chlorhexidine in alcohol
Triad Plus Sterile Skin Protectant Prep Pads prepares the skin for improved adhesion of a bandage or dressing. When dry, it leaves a thin film on the skin's surface. This provides a clean surface and
...opyl Alcohol 70% USP and 10% Acetone Alcoh...eptic, anti-infective prior to administering injec...al of oils and fats from the skin. They are gamma ...o contain a consistent amount of alcohol &acetone ...
Triad Plus Sterile Isopropyl Alcohol 70% USP Prep Pads are medium size. Each package is terminally sterilized, ensuring the safest possible product.
Medicine Products: